Foley Todd — SEC Form 4 filings
SEC reporting owner CIK 1473930. 8 Form 4 filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-12-12 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 232,870 shares, $4,191,660 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 16 legs across 7 filings — 1,172,823 shares, $9,598,981 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
- Largest priced transaction: sale of 630,191 shares @ $8.06 ($5,079,339) in iTeos Therapeutics, Inc., filed 2025-05-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| iTeos Therapeutics, Inc. (ITOS) | — | 1 | — | 1 leg · 630,191 sh · $5,079,339 | — |
| Entrada Therapeutics, Inc. (TRDA) | 10% owner | 5 | — | 14 legs · 540,669 sh · $4,517,581 | — |
| Aktis Oncology, Inc. (AKTS) | Director, 10% owner | 1 | 1 leg · 232,870 sh · $4,191,660 | — | 6 |
| Werewolf Therapeutics, Inc. (HOWL) | 10% owner | 1 | — | 1 leg · 1,963 sh · $2,061 | 3 |
Form 4 filings — Foley Todd
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 38,500 @ $7.11 · Sale (S): 192,500 @ $7.41 · Sale (S): 28,837 @ $7.13 | EDGAR |
| 2026-09-03 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 29,088 @ $7.06 · Sale (S): 25,131 @ $7.19 · Sale (S): 32,263 @ $7.17 | EDGAR |
| 2026-08-31 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 38,922 @ $7.20 · Sale (S): 3,733 @ $7.01 · Sale (S): 44,259 @ $6.99 | EDGAR |
| 2026-08-26 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 21,623 @ $7.34 · Sale (S): 26,522 @ $7.54 · Sale (S): 14,569 @ $7.06 | EDGAR |
| 2026-01-14 | 4 | Aktis Oncology, Inc. (AKTS) | Conversion (C): 597,391 · Conversion (C): 2,688,270 · Conversion (C): 716,872 · Purchase (P): 232,870 @ $18 · Conversion (C): 2,272,727 (derivative) @ $0 · Conversion (C): 10,227,273 (derivative) @ $0 · +1 more | EDGAR |
| 2025-05-15 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 GP LLC, MPM BioVentures 2014 LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, EVNIN LUKE | Sale (S): 630,191 @ $8.06 | EDGAR |
| 2025-04-30 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM Asset Management Investors BV2014 LLC | Option exercise/expiry (X): 22,758 @ $0.09 · Sale (S): 1,963 @ $1.05 · Option exercise/expiry (X): 4,015 (derivative) @ $0 · Option exercise/expiry (X): 18,743 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 22,935 @ $20.77 · Sale (S): 21,787 @ $20.23 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1473930 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →